Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase II Study of High Dose Vitamin C Intravenous Infusion in Patients with Resectable or Metastatic Solid Tumor Malignancies

Clinical Trial Details

This clinical trial is for men and women with resectable or metastatic solid tumor malignancies. The objective of the study is to investigate whether high dose vitamin C infusion leads to pathological tumor response in resectable colorectal, pancreatic, and lung cancers.

Patients will receive high dose Vitamin C infusion for 4 days per week for 2-4 consecutive weeks prior to surgery. A tumor sample will be resected after completion of study drug (high dose vitamin C infusion) treatment to examine the effects of study drug. In addition, organoids will be grown in vitro and continue to be treated with vitamin C added in culture medium to examine tumor response. 

Key Eligibility: 
  • Men and women age 18 and older
  • Patients with histologically proven early stage or locally advanced colorectal adenocarcinoma, lung cancer or pancreatic cancer, who are eligible for resection, and have not received chemotherapy or radiotherapy (cohort A)
  • Patients with metastatic colorectal cancer with an extended RAS (e.g. KRAS or NRAS) or BRAF mutation with liver metastases amenable to Y90 radioembolization (cohort C)

Detailed eligibility reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan


Carina Puello, RN
(646) 962-3541

Li Mow
(646) 962-3378



Lina Flores, RN
(718) 965-9859

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group